article thumbnail

STAT+: ‘Learning each other’s language’: FDA, patent office seek to work together to lower drug prices

STAT

But like any pharmaceutical company with an eye toward the future, Celgene continued to seek other ways to wring profits from its development work. Not long after the patent was awarded, the company leveraged federally funded research and began investigating different forms of the compound, called Revlimid.

article thumbnail

Servier beefs up in cancer, buying Agios’ oncology business for $1.8bn

pharmaphorum

French pharmaceutical company Servier has swooped on Agios Pharma’s marketed and experimental cancer drugs, buying the entire franchise in a deal that leaves the US biopharma focused on genetic disorders.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Speaking of Medicine – Mid-Year OPDP Enforcement Review

Eye on FDA

There are two means of gaining insight into the agency’s thinking about regulatory issues related to promotional communications by pharmaceutical companies; one is through the issuance of guidance documents, the other is through enforcement. But when it comes to enforcement things have changed greatly over the years.

article thumbnail

Precision Value & Health acquires Across Health

pharmaphorum

The company’s solutions are based around its proprietary Navigator365 product suite, which more than 40 pharmaceutical companies rely on for omnichannel planning and resource allocation.

article thumbnail

Halting Europe’s essential medicines manufacturing exodus

European Pharmaceutical Review

This left pharmaceutical companies in Europe with no European API supply source, and only a few suppliers in Asia. The last paracetamol plant in Europe, closed in France in 2008 as it was no longer economically sustainable, marking the exit of paracetamol manufacturing from Europe.

article thumbnail

Country focus: China & APAC’s growing medical needs bring opportunities and challenges

pharmaphorum

At the same time, lots of people with experience at multinational pharmaceutical companies have chosen to return home. All these factors will support the growth of in-house R&D-driven pharmaceutical companies and bring more innovative drugs to Asian markets.”.

article thumbnail

Japan’s M&A Boom

Pharmaceutical Technology

“The business integration from 2005 to 2007 of the two separate companies to form the joint Daiichi Sankyo created one of Japan’s biggest pharmaceutical companies.” “Local generic companies such as Ranbaxy and DRL have expanded through acquisition in Western markets aggressively in 2006.”